What is MONJUVI?: MONJUVI (tafasitamab-cxix) is a prescription medicine given with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who cannot receive a stem cell transplant.
It is not known if MONJUVI is safe and effective in children.
The approval of MONJUVI is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of MONJUVI.
My MISSION Support provides support—including financial assistance for people who are eligible, ongoing education, and other resources—throughout the treatment journey. Remember that your healthcare team is the single best source of medical advice regarding your health.
How to EnrollImportant information I should know, including possible side effects, about MONJUVI:
MONJUVI may cause serious side effects, including infusion-related reactions, low blood cell counts, and infections.
The most common side effects of MONJUVI include feeling tired or weak, diarrhea, cough, fever, swelling of lower legs or hands, respiratory tract infection, and decreased appetite.
These are not all the possible side effects of MONJUVI. Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions. If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions. Your healthcare provider may need to delay or completely stop treatment with MONJUVI if you have severe side effects.
Before receiving MONJUVI, tell your healthcare provider about all your medical conditions, including if you have an active infection or have had one recently, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. You should not become pregnant or breastfeed during treatment with MONJUVI and should use an effective method of birth control (contraception) and not breastfeed during and for at least 3 months after your last dose of MONJUVI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with MONJUVI. Refer to the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.
Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to MORPHOSYS US INC. at (844) 667-1992.
Please see the full Prescribing Information, including Patient Information, for additional Important Safety Information.
MONJUVI (tafasitamab-cxix) is a prescription medicine given with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who cannot receive a stem cell transplant.
It is not known if MONJUVI is safe and effective in children.
The approval of MONJUVI is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of MONJUVI.
Important information I should know, including possible side effects, about MONJUVI:
MONJUVI may cause serious side effects, including infusion-related reactions, low blood cell counts, and infections.
The most common side effects of MONJUVI include feeling tired or weak, diarrhea, cough, fever, swelling of lower legs or hands, respiratory tract infection, and decreased appetite.
These are not all the possible side effects of MONJUVI. Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions. If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions. Your healthcare provider may need to delay or completely stop treatment with MONJUVI if you have severe side effects.
Before receiving MONJUVI, tell your healthcare provider about all your medical conditions, including if you have an active infection or have had one recently, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. You should not become pregnant or breastfeed during treatment with MONJUVI and should use an effective method of birth control (contraception) and not breastfeed during and for at least 3 months after your last dose of MONJUVI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with MONJUVI. Refer to the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.
Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to MORPHOSYS US INC. at (844) 667-1992.
Please see the full Prescribing Information, including Patient Information, for additional Important Safety Information.
MONJUVI (tafasitamab-cxix) is a prescription medicine given with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who cannot receive a stem cell transplant.
It is not known if MONJUVI is safe and effective in children.
The approval of MONJUVI is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of MONJUVI.
You are now leaving this site and moving to an external website independently operated and not managed by MorphoSys. MorphoSys assumes no responsibility for the site.
If you would like to continue to the site, select "OK." If you do not wish to leave this site, select "Cancel."
OK CancelYou are now leaving this site and moving to an external website independently operated and not managed by MorphoSys. MorphoSys assumes no responsibility for the site.
If you would like to continue to the site, select "OK." If you do not wish to leave this site, select "Cancel."
OK CancelFor any questions on MY MISSION support or program enrollment, please call:
855-421-6172Monday to Friday, 8 AM to 8 PM ET
To receive benefits under the Copay Assistance Program, the patient must enroll in the My MISSION Support Copay Assistance Program and be accepted as eligible.
